The current financial score of Nuvation Bio Inc is 7.51. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 31.69M, representing a year-over-year increase of 555.64%, while its net profit experienced a year-over-year increase of 6.50%.
The current valuation score of Nuvation Bio Inc is 8.54. Its current P/E ratio is -13.72, which is -94.51% below the recent high of -0.75 and -39.69% above the recent low of -19.17.
The current earnings forecast score of Nuvation Bio Inc is 8.17. The average price target is 13.10, with a high of 21.00 and a low of 7.00.
The current price momentum score of Nuvation Bio Inc is 5.07. Currently, the stock price is trading between the resistance level at 6.81 and the support level at 5.26, making it suitable for range-bound swing trading.
The current institutional shareholding score of Nuvation Bio Inc is 5.00. The latest institutional shareholding proportion is 65.58%, representing a quarter-over-quarter decrease of 0.61%. The largest institutional shareholder is David Abrams, holding a total of 1.27M shares, representing 0.13% of shares outstanding, with 10.64% increase in holdings.
The current risk assessment score of Nuvation Bio Inc is 4.78. The company's beta value is 1.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.